Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs Insulin for Hepatic Steatosis in Type 2 Diabetes
NCT01399645Phase 2Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- May 2011
- Primary completion
- Jun 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liraglutide in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Liver fat fraction evolution at 12 weeks. Started May 2011; status: completed.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01399645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399645.